Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy.
5/1/2014 J Transl Med. 2014 May 13;12:127. Wagner SC, Markosian B, Ajili N, Dolan BR, Kim AJ, Alexandrescu DT, Dasanu CA, Minev B, Koropatnick J, Marincola FM, Riordan NH. Interleukin-2 (IL-2) therapy has been demonstrated to induce responses in 10-20% of advanced melanoma and renal cell carcinoma patients, which translates into durable remissions in up…
Orthomolecular oncology review: ascorbic acid and cancer 25 years later.
3/1/2005 Integr Cancer Ther. 2005 Mar;4(1):32-44 González MJ, Miranda-Massari JR, Mora EM, Guzmán A, Riordan NH, Riordan HD, Casciari JJ, Jackson JA, Román-Franco A. The effect of ascorbic acid on cancer has been a subject of great controversy. This is a follow-up review of the 1979 article by Cameron, Pauling, and Leibovitz published in Cancer…
Intravenous ascorbic acid: protocol for its application and use.
9/1/2003 P R Health Sci J. 2003 Sep;22(3):287-90 Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, González MJ, Miranda-Massari JR, Mora EM, Rosario N, Rivera A. High dose intravenous(i.v.) ascorbic acid (AA) has been used as therapy for infectious disease from bacterial and viral origin and adjuvant therapy for…
